The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 receptor agonists.

The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an assessment of how the drugs affect 175 conditions

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has uncovered neurological and behavioral health benefits amid risks for pancreatitis and kidney disease.

Novo Nordisk ( NYSE:NVO) and Eli Lilly ( NYSE:LLY) are making headlines againthis time, for potential benefits beyond weight loss. A new study finds that people taking GLP-1 medications like Ozempic, Wegovy, and Mounjaro face up to a 12% lower risk of developing Alzheimer's disease.

In all, researchers found that people taking GLP-1 medications had lower risks for 42 health outcomes, including liver failure, lung failure, cardiac arrest, aspiration pneumonia and shock.

According to a Nature Medicine study, weight loss drugs can be highly effective in improving several unexpected health conditions. Dr. Anthony Harris discusses why he believes the FDA should update the drug's label to include other conditions it can treat.

GLP-1 drugs like Ozempic and Wegovy were initially used — and still are used — to treat diabetes. But in recent years, the uses of this class of drugs have grown in number. Nowadays, Ozempic and its ilk are often used for weight loss — and have shown promise in addressing other health issues.